232 related articles for article (PubMed ID: 37938546)
1. Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells.
Chrisochoidou Y; Roy R; Farahmand P; Gonzalez G; Doig J; Krasny L; Rimmer EF; Willis AE; MacFarlane M; Huang PH; Carragher NO; Munro AF; Murphy DJ; Veselkov K; Seckl MJ; Moffatt MF; Cookson WOC; Pardo OE
Cell Death Dis; 2023 Nov; 14(11):725. PubMed ID: 37938546
[TBL] [Abstract][Full Text] [Related]
2. Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin.
Ries A; Flehberger D; Slany A; Pirker C; Mader JC; Mohr T; Schelch K; Sinn K; Mosleh B; Hoda MA; Dome B; Dolznig H; Krupitza G; Müllauer L; Gerner C; Berger W; Grusch M
J Exp Clin Cancer Res; 2023 Jan; 42(1):27. PubMed ID: 36683050
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.
Schelch K; Hoda MA; Klikovits T; Münzker J; Ghanim B; Wagner C; Garay T; Laszlo V; Setinek U; Dome B; Filipits M; Pirker C; Heffeter P; Selzer E; Tovari J; Torok S; Kenessey I; Holzmann K; Grasl-Kraupp B; Marian B; Klepetko W; Berger W; Hegedus B; Grusch M
Am J Respir Crit Care Med; 2014 Oct; 190(7):763-72. PubMed ID: 25188816
[TBL] [Abstract][Full Text] [Related]
4. Extracellular Vesicles Isolated from Malignant Mesothelioma Cancer-Associated Fibroblasts Induce Pro-Oncogenic Changes in Healthy Mesothelial Cells.
Chernova T; Grosso S; Sun XM; Tenor AR; Cabeza JZ; Craxton A; Self EL; Nakas A; Cain K; MacFarlane M; Willis AE
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293328
[TBL] [Abstract][Full Text] [Related]
5. Cancer-Associated Fibroblasts Regulate Kinase Activity in Mesothelioma Cell Lines via Paracrine Signaling and Thereby Dictate Cell Faith and Behavior.
Mathilakathu A; Wessolly M; Mairinger E; Uebner H; Kreidt D; Brcic L; Steinborn J; Greimelmaier K; Wohlschlaeger J; Schmid KW; Mairinger FD; Borchert S
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328699
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of cisplatin-induced cell death in malignant mesothelioma cells: role of inhibitor of apoptosis proteins (IAPs) and caspases.
Cregan IL; Dharmarajan AM; Fox SA
Int J Oncol; 2013 Feb; 42(2):444-52. PubMed ID: 23229133
[TBL] [Abstract][Full Text] [Related]
7. Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.
Cregan S; Breslin M; Roche G; Wennstedt S; MacDonagh L; Albadri C; Gao Y; O'Byrne KJ; Cuffe S; Finn SP; Gray SG
Int J Oncol; 2017 Mar; 50(3):1044-1052. PubMed ID: 28197626
[TBL] [Abstract][Full Text] [Related]
8. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Shapiro IM; Kolev VN; Vidal CM; Kadariya Y; Ring JE; Wright Q; Weaver DT; Menges C; Padval M; McClatchey AI; Xu Q; Testa JR; Pachter JA
Sci Transl Med; 2014 May; 6(237):237ra68. PubMed ID: 24848258
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.
Szymiczek A; Carbone M; Pastorino S; Napolitano A; Tanji M; Minaai M; Pagano I; Mason JM; Pass HI; Bray MR; Mak TW; Yang H
Oncogene; 2017 Nov; 36(46):6501-6507. PubMed ID: 28759042
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Src family kinases overcomes anoikis resistance induced by spheroid formation and facilitates cisplatin-induced apoptosis in human mesothelioma cells.
Eguchi R; Fujita Y; Tabata C; Ogawa H; Wakabayashi I; Nakano T; Fujimori Y
Oncol Rep; 2015 Nov; 34(5):2305-10. PubMed ID: 26323315
[TBL] [Abstract][Full Text] [Related]
13. Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed.
Ando H; Kobayashi S; Abu Lila AS; Eldin NE; Kato C; Shimizu T; Ukawa M; Kawazoe K; Ishida T
J Control Release; 2015 Dec; 220(Pt A):29-36. PubMed ID: 26476173
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
[TBL] [Abstract][Full Text] [Related]
15. Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma.
Chia PL; Russell PA; Scott AM; John T
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1235-1245. PubMed ID: 27696931
[TBL] [Abstract][Full Text] [Related]
16. 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
Gerogianni I; Pitaraki E; Jagirdar RM; Kouliou O; Giannakou L; Giannopoulos S; Papazoglou E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
Anticancer Res; 2019 Jul; 39(7):3809-3814. PubMed ID: 31262908
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma].
Zeng X; Jiang Z; Duan J
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
[TBL] [Abstract][Full Text] [Related]
18. Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.
Greening DW; Ji H; Chen M; Robinson BW; Dick IM; Creaney J; Simpson RJ
Sci Rep; 2016 Sep; 6():32643. PubMed ID: 27605433
[TBL] [Abstract][Full Text] [Related]
19. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma.
Vanbervliet-Defrance B; Delaunay T; Daunizeau T; Kepenekian V; Glehen O; Weber K; Estornes Y; Ziverec A; Djemal L; Delphin M; Lantuéjoul S; Passot G; Grégoire M; Micheau O; Blanquart C; Renno T; Fonteneau JF; Lebecque S; Mahtouk K
Cancer Lett; 2020 Mar; 472():29-39. PubMed ID: 31838086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
